Expansion of α-galactosylceramide-stimulated Vα24+ NKT cells cultured in the absence of animal materials

被引:8
|
作者
Harada, Y
Imataki, O
Heike, Y
Kawai, H
Shimosaka, A
Mori, SI
Kami, M
Tanosaki, R
Ikarashi, Y
Iizuka, A
Yoshida, M
Wakasugi, H
Saito, S
Takaue, Y
Takei, M
Kakizoe, T
机构
[1] Natl Canc Ctr, Blood & Stem Cell Transplantat Unit, Hematopoiet Stem Cell Transplant Immunotherapy Un, Natl Canc Ctr,Res Inst,Chuo Ku, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Res Inst, Div Pharmacol, Tokyo 104, Japan
[3] Kirin Brewery Co Ltd, Tokyo, Japan
[4] Toyama Med & Pharmaceut Univ, Dept Obstet & Gynecol, Toyama, Japan
关键词
NKT cells; G-CSF; alpha-galactosylceramide;
D O I
10.1097/01.cji.0000163593.66910.ad
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
V alpha 24(+) NKT is an innate lymphocyte with potential antitumor activity. Clinical applications of V alpha 24(+) natural killer (NK) T cells, which are innate lymphocytes with potential antitumor activity, require their in vitro expansion. To avoid the potential dangers posed to patients by fetal bovine serum (FBS), the authors evaluated non-FBS culture conditions for the selective and efficient expansion of human V alpha 24(+) NKT cells. Mononuclear cells (MNCs) and plasma from the peripheral blood of normal healthy donors were used before and after G-CSF mobilization. MNCs and plasma separated from apheresis products were also used. MNCs were cultured for 12 days in AIM-V medium containing alpha-galactosylceramide (alpha-GalCer) (100 ng/mL) and IL-2 (100 U/mL) supplemented with FBS, autologous plasma, or autologous serum. The cultured cells were collected and their surface markers, intracellular cytokines, and cytotoxicity were evaluated. The highest expansion ratio for V alpha 24(+) NKT cells was obtained from G-CSF-mobilized MNCs cultured in medium containing 5% autologous plasma. Cultures containing MNCs and autologous plasma obtained before and after G-CSF mobilization had approximately 350-fold and 2,000-fold expansion ratios, respectively. These results suggest that G-CSF mobilization conferred a proliferative advantage to V alpha 24(+) NKT cells by modifying the biology of cells and plasma factors. Expanded Va24' NKT cells retained their surface antigen expression and production of IFN-gamma and exhibited CD1d-independent cytotoxicity against tumor cells. V alpha 24(+) NKT cells can be efficiently expanded from G-CSF-mobilized peripheral blood MNCs in non-FBS culture conditions with a-GalCer and IL-2.
引用
收藏
页码:314 / 321
页数:8
相关论文
共 25 条
  • [21] Vα24 NKT cells from human blood undergo CD1D and Vα24 TCR restricted proliferation in response to α-galactosylceramide and have a unique mechanism of cytotoxic antitumor activity.
    Nieda, M
    Nicol, A
    Takahashi, T
    Kikuchi, A
    Yabe, T
    Koezuka, Y
    Ishikawa, Y
    Suzuki, K
    Hirai, H
    Takokoro, K
    Juji, T
    BLOOD, 1998, 92 (10) : 26A - 26A
  • [22] Human invariant Vα24+ natural killer T cells activated by α-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells
    Nicol, A
    Nieda, M
    Koezuka, Y
    Porcelli, S
    Suzuki, K
    Tadokoro, K
    Durrant, S
    Juji, T
    IMMUNOLOGY, 2000, 99 (02) : 229 - 234
  • [23] Insufficient ex vivo expansion of Vα24+ natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14+ cells
    Imataki, O.
    Heike, Y.
    Makiyama, H.
    Iizuka, A.
    Ikarashi, Y.
    Ishida, T.
    Wakasugi, H.
    Takaue, Y.
    CYTOTHERAPY, 2008, 10 (05) : 497 - 506
  • [24] Insufficient ex vivo expansion of Vα24+ natural killer T cells in cancer patients may be related to the suppressed expression of CD1d molecules on CD14+ cells.
    Imataki, O
    Heike, Y
    Takaue, Y
    Wakasugi, H
    BLOOD, 2005, 106 (11) : 311A - 311A
  • [25] Expansion of Vα24+Vβ11+ NKT cells from cord blood mononuclear cells using IL-15, IL-7 and Flt3-L depends on monocytes
    Okada, H
    Nagamura-Inoue, T
    Mori, Y
    Takahashi, TA
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2006, 36 (01) : 236 - 244